Sort   by:  
 Page size 
UnknownSwitching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Not available
S-EPMC11561219 | biostudies-literature
Unknown104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Not available
S-EPMC11055775 | biostudies-literature
UnknownCollaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression.
Not available
S-EPMC5628077 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
UnknownBaricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998 | biostudies-literature
UnknownImpact of postoperative acute kidney injury in patients undergoing major gastrointestinal surgery on 1-year survival and renal outcomes: a national multicentre cohort study.
Not available
S-EPMC8759520 | biostudies-literature
UnknownChallenges of one-year longitudinal follow-up of a prospective, observational cohort study using an anonymised database: recommendations for trainee research collaboratives.
Not available
S-EPMC6909648 | biostudies-literature
UnknownFatal and Nonfatal Events Within 14 days After Early, Intensive Mobilization Poststroke.
Not available
S-EPMC8055346 | biostudies-literature
UnknownResidual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury.
Not available
S-EPMC12860639 | biostudies-literature
UnknownAI is a viable alternative to high throughput screening: a 318-target study.
Not available
S-EPMC10987645 | biostudies-literature
Sort   by:  
 Page size